{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:09Z","timestamp":1792088169304,"version":"4.4.0"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,10]]},"DOI":"10.18632\/oncotarget.13824","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T20:24:35Z","timestamp":1481401475000},"page":"3042-3048","source":"Crossref","is-referenced-by-count":26,"title":["Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus"],"prefix":"10.18632","volume":"8","author":[{"given":"Chin-Hsiao","family":"Tseng","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan"},{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Division of Environmental Health and Occupational Medicine of the National Health Research Institutes, Zhunan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,12,8]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2174\/187152012803529664","article-title":"The role of peroxisome proliferator-activated receptor-\u03b3 in breast cancer","volume":"12","author":"Theocharis","year":"2012","journal-title":"Anticancer Agents Med Chem"},{"key":"2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/CEJ.0b013e32833ca233","article-title":"Pioglitazone in chemically induced mammary carcinogenesis in rats","volume":"19","author":"Ahlers","year":"2010","journal-title":"Eur J Cancer Prev"},{"key":"3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12094-009-0347-5","article-title":"Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis","volume":"11","author":"Guner","year":"2009","journal-title":"Clin Transl Oncol"},{"key":"4","first-page":"5","article-title":"Macrophage PPAR\u03b3 inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone","volume":"3","author":"Wan","year":"2016","journal-title":"Elife"},{"key":"5","doi-asserted-by":"crossref","first-page":"159415","DOI":"10.1155\/2008\/159415","article-title":"Clinical Use of PPARgamma Ligands in Cancer","volume":"2008","author":"Yee","year":"2008","journal-title":"PPAR Res"},{"key":"6","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2337\/dc07-2308","article-title":"Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials","volume":"31","author":"Mannucci","year":"2008","journal-title":"Diabetes Care"},{"key":"7","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","article-title":"Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study","volume":"55","author":"Allemand","year":"2012","journal-title":"Diabetologia"},{"key":"8","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1002\/ijc.21799","article-title":"Increased PTEN expression due to transcriptional activation of PPARgamma by lovastatin and rosiglitazone","volume":"118","author":"Eng","year":"2006","journal-title":"Int J Cancer"},{"key":"9","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2337\/dc10-1067","article-title":"Cohort study of pioglitazone and cancer incidence in patients with diabetes","volume":"34","author":"Habel","year":"2011","journal-title":"Diabetes Care"},{"key":"10","first-page":"67","article-title":"Benign breast diseases, contraception and hormone replacement therapy","volume":"64","author":"Genazzani","year":"2012","journal-title":"Minerva Ginecol"},{"key":"11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/jnci\/djs014","article-title":"Changing concepts: Menopausal hormone therapy and breast cancer","volume":"104","author":"Anderson","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-010-1074-x","article-title":"Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study","volume":"126","author":"Cerhan","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3132\/dvdr.2007.001","article-title":"The insulin resistance syndrome: physiological considerations","volume":"4","author":"Defronzo","year":"2007","journal-title":"Diab Vasc Dis Res"},{"key":"14","first-page":"789174","article-title":"Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms","volume":"2012","author":"Brunetti","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00125-008-1204-8","article-title":"Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006","volume":"52","author":"Tai","year":"2009","journal-title":"Diabetologia"},{"key":"16","doi-asserted-by":"crossref","first-page":"823S","DOI":"10.1093\/ajcn\/86.3.823S","article-title":"Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence","volume":"86","author":"Michels","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"17","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/ijc.24609","article-title":"Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer","volume":"125","author":"Rohan","year":"2009","journal-title":"Int J Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/1940-6207.CAPR-14-0334","article-title":"Leptin and adiponectin modulate the self-renewal of normal human breast epithelial stem cells","volume":"8","author":"Brenner","year":"2015","journal-title":"Cancer Prev Res (Phila)"},{"key":"19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12020-008-9058-x","article-title":"Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones","volume":"33","author":"Imamoglu","year":"2008","journal-title":"Endocrine"},{"key":"20","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1463-1326.2008.00880.x","article-title":"Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients","volume":"10","author":"DeFronzo","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10549-014-2985-8","article-title":"Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes","volume":"145","author":"Tseng","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"22","first-page":"678756","article-title":"Use of insulin and mortality from breast cancer among Taiwanese women with diabetes","author":"Tseng","year":"2015","journal-title":"J Diabetes Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1186\/s12885-015-1876-7","article-title":"Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes","volume":"15","author":"Tseng","year":"2015","journal-title":"BMC Cancer"},{"key":"24","first-page":"413782","article-title":"The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese","volume":"2012","author":"Tseng","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Strom","year":"2011","journal-title":"Diabetes Care"},{"key":"26","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Wilhelmsen","year":"2005","journal-title":"Lancet"},{"key":"27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jfma.2011.10.003","article-title":"Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?","volume":"111","author":"Tseng","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10590501.2014.877645","article-title":"A review on thiazolidinediones and bladder cancer in human studies","volume":"32","author":"Tseng","year":"2014","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev"},{"key":"29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/10590501.2012.735519","article-title":"Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies","volume":"30","author":"Tseng","year":"2012","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev"},{"key":"30","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Wolski","year":"2007","journal-title":"N Engl J Med"},{"key":"31","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2337\/dc11-1449","article-title":"Pioglitazone and bladder cancer: a population-based study of Taiwanese","volume":"35","author":"Tseng","year":"2012","journal-title":"Diabetes Care"},{"key":"32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2407-13-7","article-title":"Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan","volume":"13","author":"Tseng","year":"2013","journal-title":"BMC Cancer"},{"key":"33","doi-asserted-by":"crossref","first-page":"e53096","DOI":"10.1371\/journal.pone.0053096","article-title":"Thyroid cancer risk is not increased in diabetic patients","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1530\/EJE-12-0369","article-title":"Diabetes, metformin use, and colon cancer: A population-based cohort study in Taiwan","volume":"167","author":"Tseng","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"35","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00125-011-2171-z","article-title":"Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan","volume":"54","author":"Tseng","year":"2011","journal-title":"Diabetologia"},{"key":"36","doi-asserted-by":"publisher","first-page":"40767","DOI":"10.18632\/oncotarget.8194","article-title":"Repurposing metformin for cancer treatment: current clinical studies","volume":"7","author":"Giles","year":"2016","journal-title":"Oncotarget"},{"key":"37","doi-asserted-by":"publisher","first-page":"66202","DOI":"10.18632\/oncotarget.11033","article-title":"Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis","volume":"7","author":"Tan","year":"2016","journal-title":"Oncotarget"},{"key":"38","doi-asserted-by":"publisher","first-page":"59548","DOI":"10.18632\/oncotarget.10934","article-title":"Metformin use and cervical cancer risk in female patients with type 2 diabetes","volume":"7","author":"Tseng","year":"2016","journal-title":"Oncotarget"},{"key":"39","doi-asserted-by":"publisher","first-page":"49636","DOI":"10.18632\/oncotarget.10421","article-title":"Metformin as a new anti-cancer drug in adrenocortical carcinoma","volume":"7","author":"Luconi","year":"2016","journal-title":"Oncotarget"},{"key":"40","doi-asserted-by":"publisher","first-page":"54096","DOI":"10.18632\/oncotarget.10262","article-title":"Metformin and cancer: Quo vadis et cui bono?","volume":"7","author":"Joven","year":"2016","journal-title":"Oncotarget"},{"key":"41","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.18632\/oncotarget.6626","article-title":"Metformin may reduce oral cancer risk in patients with type 2 diabetes","volume":"7","author":"Tseng","year":"2016","journal-title":"Oncotarget"},{"key":"42","doi-asserted-by":"publisher","first-page":"39398","DOI":"10.18632\/oncotarget.6347","article-title":"Metformin for cancer and aging prevention: is it a time to make the long story short?","volume":"6","author":"Anisimov","year":"2015","journal-title":"Oncotarget"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T03:43:34Z","timestamp":1718941414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,8]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,1,10]]}},"alternative-id":["13824","27936468"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13824","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,8]]}}}